Precision Medicine Market by Technology, Application, End-User, Deployment

List of Tables

[196 Pages Report] The Precision Medicine Market size was estimated at USD 68.12 billion in 2023 and expected to reach USD 75.70 billion in 2024, at a CAGR 11.22% to reach USD 143.43 billion by 2030.

Precision medicine refers to the strategy of tailoring disease prevention and treatment solutions by considering the differences in patient's genetics, environments, and lifestyles. This concept can be utilized as an effective prevention technique for cancers, heart diseases, cystic fibrosis, and diabetes. Precision medicine is used to predict disease susceptibility, improve disease detection, and offer customized disease-prevention strategies. Government efforts to improve research and development activities in the precision medicine sector and simultaneously improve the accessibility of healthcare treatment options for lower-income individuals are increasing rapidly. Joint efforts between pharmaceutical, software, and bioinformatics companies to characterize the genes have expanded drug discovery. However, the lack of reimbursement for precision medicine-based treatment and standardized reimbursement codes and definitions hampers patient adoption and R&D activities. Additionally, the complicated FDA pharmacotherapy approval process and subsequent commercialization challenges of the product pose significant hurdles. However, efforts by government and regulatory agencies to ensure the accuracy of gene sequencing and next-generation sequencing have improved compliance with regulations. Additionally, the adoption of AI, ML, and cloud-based solutions allows researchers to use complex data from electronic health records to detect early-onset diseases, including Alzheimer's and dementia.

KEY MARKET STATISTICS
Base Year [2023]	USD 68.12 billion
Estimated Year [2024]	USD 75.70 billion
Forecast Year [2030]	USD 143.43 billion
CAGR (%)	11.22%

Technology: Big data analytics is advancing the field of precision medicine

Big data analytics and bioinformatics technologies utilize molecular, clinical, and digital data derived from experimentation and electronic health records for the development of precision medicines and therapies. Companion diagnostics refer to tests used to detect specific genetic mutations and biomarkers in patients who have a higher probability of responding to precision medicine treatment techniques. Gene sequencing and Next-generation sequencing are utilized in precision medicine to sequence multiple genes and identify disease-associated gene mutations to facilitate matching of patients to appropriate therapies.

Application: Personalized cancer and oncology care using precision medicine

Precision medicine for the treatment of CNS disorders can be used to facilitate comprehensive genetic assessment, identifying biomarkers, and modification of treatments according to the patient's genetics. Immune disorders, including Inflammatory Bowel Disease (IBD) and Systemic Lupus Erythematosus, can be effectively targeted by precision medicine by evaluation of biomarkers implicated in these diseases. Colorectal cancer, stomach cancer, and lung cancer can be tackled by utilization of a personalized medicine regime that offers individualized treatment options tailored to specific tissues, genetic mutations, and factors relevant to each case of cancer. For respiratory diseases, precision medicine has been used for the assessment of patients for bronchoscopic or surgical interventions such as bronchoscopic lung volume reduction and lung volume reduction surgery.

End-user: Efforts by biotechnology and diagnostic companies to invest in R&D and advance the field of precision medicine

Major biotechnology and diagnostic companies are developing personalized cancer therapeutics and personalized vaccines and are involved in R&D activities related to drug discovery. Evolving scientific and technological advancements have propelled the utilization of precision medicine in laboratories and pharmaceuticals for personalized disease diagnosis and subsequent development of appropriate treatment regimes for the patient. Major research centers and government institutions are focusing on developing collaborative research to understand the causes of common diseases, including heart disease, diabetes, obesity, and other aging-related morbidities.

Deployment: Integration of AI and cloud solutions to improve efficacy and speed of development of precision medicine services

Cloud computing and the integration of AI have led to the generation of genomic cloud solutions that allow clinicians to analyze larger patient datasets, even in remote settings. Deployment of precision medicine solutions through on-cloud platforms improves the analysis efficiency. The utilization of cloud solutions for the detection of diseases such as Alzheimer's and dementia in advance is gaining attention. On-premise deployment of precision medicine involves the utilization of data generated during NGS analysis and omics experiments and stored in institutional databases.

Regional Insights

Countries in the Americas are increasing the focus on the integration of AI and ML in precision medicine for the treatment and management of cancers and tumors. Government efforts in the Americas has propelled the deployment of precision medicine by clinicians and physicians for treatment purposes. Mexico and Colombia are exerting efforts to analyze the entire genetic constitution of the citizens to better equip medical and research personnel with medical decision-making. In the APAC region, emerging economies, including India and China, are increasing investment in gene therapy research and developing products such as microbots that aim to support precision medicine delivery. These countries are also experiencing a rising number of cancer care clinics and hospitals that utilize precision medicine to guide patient diagnosis and treatment. The Japanese government aims to promote the linkage of medical records, including medical genomic testing data and personal health records (PHRs), which can improve the development of precision medicines and drugs. In the European nations of UK, Germany, and Switzerland, the presence of robust research institutions and focus of academic institutions on novel research is responsible for driving the development of personalized treatment regimes and medicines. The provision of precision medicine solutions by major pharmaceutical and biotechnological companies located in European nations has allowed the region to solidify its position in the life sciences sector.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Precision Medicine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Precision Medicine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Precision Medicine Market, highlighting leading vendors and their innovative profiles. These include AccessDX Holdings, Adaptive Biotechnologies Corporation, Biocrates Life Sciences AG, bioMerieux SA, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Foundation Medicine, Inc., Guardant Health, Inc., healthOme, Illumina, Inc., Intomics by ZS Associates, Inc., Invitae Corporation., Laboratory Corporation of America Holdings, Medtronic PLC, Natera Inc., Novartis AG, Pfizer Inc., Precision Medicine Group, LLC, QIAGEN GmbH, Quest Diagnostics Incorporated, Strata Oncology, Inc., Syapse, Inc., Tempus Labs, Inc., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Precision Medicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology
- Big Data Analytics
- Bioinformatics
- Companion Diagnostics
- Drug Discovery
- Gene Sequencing

Application
- CNS
- Immunology
- Oncology
- Respiratory

End-User
- Biotechnology & Diagnostic Companies
- Laboratories & Pharmaceuticals
- Research Centers & Government Institutions

Deployment
- On-Cloud
- On-Premise

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Precision Medicine Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Precision Medicine Market?

3. What are the technology trends and regulatory frameworks in the Precision Medicine Market?

4. What is the market share of the leading vendors in the Precision Medicine Market?

5. Which modes and strategic moves are suitable for entering the Precision Medicine Market?

Product Code: MRR-030EE48515D0

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising government funding and rising online collaborative forums
  - 5.1.1.2. Increasing use of artificial intelligence in precision medicine
  - 5.1.1.3. Advancement in cancer biology complemented by the active presence of startups
- 5.1.2. Restraints
  - 5.1.2.1. Lack of reimbursement for precision medicine-based treatment
- 5.1.3. Opportunities
  - 5.1.3.1. Growing adoption of cloud-based solutions in precision medicine
  - 5.1.3.2. Strategic alliances among pharmaceutical and software companies to characterize the genes
- 5.1.4. Challenges
  - 5.1.4.1. Complicated FDA pharmacotherapy approval rate
5.2. Market Segmentation Analysis
- 5.2.1. Technology: Big data analytics is advancing the field of precision medicine
- 5.2.2. Application: Personalized cancer and oncology care using precision medicine
- 5.2.3. End-user: Efforts by biotechnology and diagnostic companies to invest in R&D and advance the field of precision medicine
- 5.2.4. Deployment: Integration of AI and cloud solutions to improve efficacy and speed of development of precision medicine services
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Precision Medicine Market, by Technology

6.1. Introduction
6.2. Big Data Analytics
6.3. Bioinformatics
6.4. Companion Diagnostics
6.5. Drug Discovery
6.6. Gene Sequencing

7. Precision Medicine Market, by Application

7.1. Introduction
7.2. CNS
7.3. Immunology
7.4. Oncology
7.5. Respiratory

8. Precision Medicine Market, by End-User

8.1. Introduction
8.2. Biotechnology & Diagnostic Companies
8.3. Laboratories & Pharmaceuticals
8.4. Research Centers & Government Institutions

9. Precision Medicine Market, by Deployment

9.1. Introduction
9.2. On-Cloud
9.3. On-Premise

10. Americas Precision Medicine Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Precision Medicine Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Precision Medicine Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Thirona Raises EUR 7.5 Million New Financing to Accelerate the Adoption of its Breakthrough Innovations for Precision Medicine
- 13.3.2. Novartis completes acquisition of precision medicine developer Chinook
- 13.3.3. New Dartmouth Center Applies AI to Improve Health Outcomes
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio